What is epithelioid sarcoma?
Epithelioid sarcoma is a rare cancer of the soft tissues. It most often starts as a small, firm lump in the fingers, hand or forearm of a teenager or young adult.
Under the microscope, the cancer cells look like epithelial cells, the cells that line the skin and organs. That is where the name “epithelioid” comes from. In fact, it is a sarcoma, a cancer of connective tissue.
Epithelioid sarcoma is often mistaken at first for a harmless condition, such as a wart, an infected nodule, a ganglion or a granuloma. This can delay the diagnosis by months or years.
It tends to come back in the same area after surgery. It can also spread along tendons, to nearby lymph nodes and to the lungs.
Almost all epithelioid sarcomas have lost a protein called INI1 (SMARCB1). This discovery led to the first targeted drug for the disease, tazemetostat.
1. Key facts at a glance
| Feature | Details |
|---|---|
| How common | Fewer than 1% of soft-tissue sarcomas |
| Typical age | Classic type: mostly 10-35. Proximal type: usually older, around 20-60 |
| Sex | More common in males |
| Main sites | Classic type: fingers, hand, wrist, forearm, lower leg and foot. Proximal type: pelvis, groin, buttock, genital area and trunk |
| Key gene change | Loss of SMARCB1 (INI1) in over 90% |
| Spread | Local spread along fascia and tendons; lymph nodes; lungs |
| Main treatments | Wide surgery, radiotherapy, tazemetostat and chemotherapy for advanced disease |
| Outlook | About half to two-thirds alive at 5 years; better for small, distal tumours |
2. Types of epithelioid sarcoma
| Feature | Classic (distal) type | Proximal type |
|---|---|---|
| Who | Adolescents and young adults | Mostly middle-aged adults |
| Where | Hands, fingers, forearms, feet | Pelvis, perineum, genital area, groin, trunk |
| Appearance | Small, firm nodules, sometimes ulcerated | Larger, deep masses |
| Cells | Nodules of cells with central necrosis, which can look like a granuloma | Large cells with a “rhabdoid” look |
| Behaviour | Slow growth, frequent local recurrence | More aggressive, with earlier spread |
| INI1 loss | Yes | Yes |
3. Causes and risk factors
The cause is not known in most people.
| Factor | Notes |
|---|---|
| SMARCB1 (INI1) loss | An acquired change in the tumour that switches off a “brake” on cell growth. It also makes the cells depend on a protein called EZH2, which tazemetostat blocks |
| Injury | Many people remember an injury to the area, but injury is not thought to cause the cancer; it may simply draw attention to the lump |
| Inherited risk | Not usually inherited |
4. How does it look?
4.1 On the skin and under it
| Feature | What it looks or feels like |
|---|---|
| Lump | A small, firm, painless nodule under the skin, often on a finger, the palm or forearm |
| Several nodules | A chain of nodules along a tendon or the forearm, as the tumour spreads along tissue planes |
| Ulcer | The skin over the lump may break down into a non-healing ulcer that can look like an infection |
| Skin colour | Usually skin-coloured; sometimes red, purple or crusted |
| Proximal type | A deep, larger swelling in the groin, buttock or genital area |
4.2 On scans
| Test | Typical findings |
|---|---|
| MRI | A soft-tissue mass, often spreading along tendons or fascia, with enhancement after contrast; there may be several nodules |
| Ultrasound | A solid nodule, often used first |
| CT chest | Looks for lung spread |
| PET-CT | May be used to look for lymph node and distant spread |
4.3 Under the microscope
| Feature | Description |
|---|---|
| Pattern | Nodules of plump cells, often with dead tissue in the centre; this can look like a granuloma |
| Cells | Epithelial-like cells with pink cytoplasm, mixed with spindle-shaped cells |
| Markers | Positive for cytokeratins and EMA (like carcinoma), often CD34 and ERG |
| INI1 stain | Loss of INI1 in the tumour cell nuclei in over 90% of cases |
5. Symptoms
| Symptom | Details |
|---|---|
| A lump | The commonest sign; slow-growing and usually painless |
| Non-healing sore | An ulcer over the lump that does not respond to antibiotics or creams |
| Several lumps | New nodules near the first one, often along the arm or hand |
| Pain or numbness | If the tumour presses on a nerve |
| Stiffness | Reduced movement of a finger or hand |
| Swollen glands | In the elbow, armpit or groin if the cancer has reached lymph nodes |
| Cough or breathlessness | Rare, with lung spread |
See a doctor for any lump that is growing, larger than 5 cm, deep, or keeps coming back after removal, or for a sore that will not heal.
5.1 Conditions it can be mistaken for
| Condition | How it differs |
|---|---|
| Wart or callus | Warts are on the skin surface; epithelioid sarcoma lies under the skin and keeps growing |
| Ganglion cyst | A ganglion is fluid-filled on ultrasound; epithelioid sarcoma is solid |
| Infection or abscess | Infections usually improve with antibiotics or drainage; the sarcoma does not |
| Granuloma annulare or rheumatoid nodule | Biopsy can look similar, but INI1 staining shows loss in epithelioid sarcoma |
| Giant cell tumour of tendon sheath | Also a lump on a finger, but benign and with a different appearance on MRI and biopsy |
| Carcinoma or melanoma | Can share markers, but the pattern of stains and INI1 loss point to epithelioid sarcoma |
Because of these look-alikes, any hand or forearm lump that grows or returns after removal should be checked with imaging and a biopsy reviewed by a sarcoma pathologist.
6. Diagnosis
| Step | Purpose |
|---|---|
| MRI | Before any biopsy, to see the extent of the tumour |
| Core needle biopsy | At or in discussion with a sarcoma centre, planned so that the biopsy track can be removed later |
| Pathology with INI1 stain | Confirms the diagnosis and separates it from carcinoma, melanoma and benign granulomas |
| CT chest | Checks for lung spread |
| Lymph node assessment | Ultrasound, PET-CT, or sometimes sentinel lymph node biopsy, as nodal spread is more common than in most sarcomas |
Lumps that are removed without planning (“whoops” excisions) often leave tumour behind. A further, wider operation is then usually needed.
6.1 Your care team
| Team member | Role |
|---|---|
| Sarcoma surgeon or hand surgeon | Plans and performs the operation, often with a plastic surgeon for reconstruction |
| Sarcoma pathologist | Confirms the diagnosis with special stains, including INI1 |
| Radiologist | Performs and reads MRI, CT and guided biopsies |
| Clinical oncologist | Plans radiotherapy |
| Medical oncologist | Advises on chemotherapy, tazemetostat and trials |
| Specialist nurse | Your main contact for questions and support |
| Hand therapist or physiotherapist | Helps restore movement and strength after treatment |
All these specialists meet in a multidisciplinary team (MDT) meeting to agree the best plan for each person.
7. Treatment
Treatment should be led by a specialist sarcoma team, in line with ESMO-EURACAN-GENTURIS guidance.
7.1 Localised disease
| Treatment | Details |
|---|---|
| Wide surgical excision | Removing the tumour with a margin of healthy tissue is the main treatment |
| Limb- and hand-sparing surgery | Usually possible; reconstruction by plastic or hand surgeons may be needed |
| Amputation | Occasionally needed, for example of a finger, when a clear margin cannot otherwise be obtained |
| Radiotherapy | Before or after surgery, especially for larger tumours or close margins; reduces local recurrence |
| Lymph node surgery | If nodes are involved |
| Chemotherapy | Sometimes considered for large or high-risk tumours, case by case |
7.2 Advanced or metastatic disease
| Treatment | Evidence and key points |
|---|---|
| Tazemetostat | An EZH2 inhibitor tablet for tumours with INI1 loss. In a phase 2 trial, about 15% had tumour shrinkage and many more had stable disease, often with good tolerance. It received accelerated US approval in 2020 |
| Anthracycline-based chemotherapy | Doxorubicin, with or without ifosfamide; responses in about 1 in 5 in an international series |
| Gemcitabine-based chemotherapy | Similar response rates |
| Pazopanib | Little activity in epithelioid sarcoma in reported series |
| Radiotherapy and surgery for metastases | To control specific sites or relieve symptoms |
| Immunotherapy and clinical trials | Being studied; INI1-deficient tumours are a research focus |
7.3 Side effects of treatment
| Treatment | Common side effects |
|---|---|
| Hand and arm surgery | Reduced grip, stiffness or numbness; hand therapy helps |
| Radiotherapy | Skin redness, later stiffness, swelling or fibrosis |
| Chemotherapy | Hair loss, nausea, low blood counts, infection risk, tiredness |
| Tazemetostat | Tiredness, nausea, pain, low appetite; a small risk of second blood cancers is monitored |
7.4 Treatment for children and adolescents
Epithelioid sarcoma is one of the non-rhabdomyosarcoma soft-tissue sarcomas of childhood. Young patients are treated in paediatric or teenage and young adult sarcoma units, often following international study group protocols.
| Point | Details |
|---|---|
| Surgery | Remains the main treatment, aiming for clear margins while protecting growth and function |
| Radiotherapy | Used selectively, as it can affect bone growth and cause long-term stiffness |
| Chemotherapy | Considered for large, high-grade or metastatic tumours |
| Tazemetostat | Approved in the United States for patients aged 16 and over with advanced disease; younger patients may access it through trials |
8. Outlook (prognosis)
| Factor | Effect on outlook |
|---|---|
| Classic distal type, small tumour, clear margins | Best outlook |
| Proximal type | Worse outlook |
| Size over 5 cm, deep tumour, necrosis | Worse |
| Lymph node or lung spread | Worse |
| Repeated local recurrence | Raises the risk of distant spread |
Overall, about 50-70% of people are alive at 5 years, but late recurrence can occur, so long follow-up is needed.
Recurrences can appear many years after treatment. Local recurrence is particularly common if the first operation did not achieve clear margins, which is one reason why surgery at a specialist sarcoma centre matters so much.
9. Follow-up
| What | How often |
|---|---|
| Clinic visit and examination of the scar and nodes | Every 3-4 months for 2-3 years, then every 6 months to 5 years, then yearly |
| MRI of the original site | Regularly in the first years |
| CT chest | Every 3-6 months at first |
| Length of follow-up | At least 10 years |
10. Living with epithelioid sarcoma
| Topic | Practical advice |
|---|---|
| Hand function | Physiotherapy and occupational therapy help recovery after hand or arm surgery |
| Checking yourself | Learn how your scar and nearby lymph nodes feel, and report new lumps early |
| Young people | Teenage and young adult cancer teams offer support with education, work and fertility |
| Support | Sarcoma charities provide information and connect people with rare sarcomas |
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is it a skin cancer? | No. It is a soft-tissue sarcoma that often lies just under the skin |
| Why was it first thought to be harmless? | Small nodules and ulcers look like common benign problems. Its rarity also makes it easy to miss |
| Will I lose my hand? | Most people keep their hand or limb. Amputation of a finger or part of a limb is occasionally needed for clear margins |
| What does INI1 loss mean? | The tumour has lost a growth-controlling protein. This is used for diagnosis and allows treatment with tazemetostat |
| Is it inherited? | Usually not |
| Can I keep working or studying? | Many people do, with time off around surgery and radiotherapy. Hand surgery may need several weeks of recovery before heavy use |
| Will radiotherapy affect my hand? | It can cause stiffness or tightness of the skin over time. Regular stretching and hand therapy reduce this |
| What if the lump comes back? | Local recurrence can often be treated with more surgery and sometimes radiotherapy. Tell your team about any new lump early |
Resources
- WHO Classification of Tumours Editorial Board (2020) Soft Tissue and Bone Tumours. 5th edn. Lyon: International Agency for Research on Cancer.
- Enzinger, F.M. (1970) ‘Epitheloid sarcoma. A sarcoma simulating a granuloma or a carcinoma’, Cancer, 26(5), pp. 1029-1041.
- Guillou, L. et al. (1997) ‘”Proximal-type” epithelioid sarcoma, a distinctive aggressive neoplasm showing rhabdoid features. Clinicopathologic, immunohistochemical, and ultrastructural study of a series’, American Journal of Surgical Pathology, 21(2), pp. 130-146.
- Hornick, J.L., Dal Cin, P. and Fletcher, C.D. (2009) ‘Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma’, American Journal of Surgical Pathology, 33(4), pp. 542-550.
- Chbani, L. et al. (2009) ‘Epithelioid sarcoma: a clinicopathologic and immunohistochemical analysis of 106 cases from the French sarcoma group’, American Journal of Clinical Pathology, 131(2), pp. 222-227.
- Gronchi, A. et al. (2021) ‘Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 32(11), pp. 1348-1365.
- Frezza, A.M. et al. (2018) ‘Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma: a multi-institutional case series’, JAMA Oncology, 4(9), e180219.
- Gounder, M. et al. (2020) ‘Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study’, The Lancet Oncology, 21(11), pp. 1423-1432.
- National Cancer Institute (2026) Adult Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.